Key result
Ramipril and bisoprolol reduce subclinical cardiac damage by up to ~78% versus placebo.
Why the study?
Anthracycline-based chemotherapy for breast cancer is associated with cardiotoxicity, including subclinical cardiac damage, prompting evaluation of cardioprotection with ramipril and bisoprolol.
Do ramipril and/or bisoprolol prevent subclinical cardiac damage in patients with nonmetastatic breast cancer undergoing anthracycline-based chemotherapy?
RCT (n=262)
Double-blind
2 × 2 factorial
Yes
Do ramipril and/or bisoprolol prevent subclinical cardiac damage in patients with nonmetastatic breast cancer undergoing anthracycline-based chemotherapy?
Ramipril and bisoprolol, alone or in combination, significantly reduce the incidence of subclinical cardiac damage in patients with nonmetastatic breast cancer undergoing anthracycline-based chemotherapy.
Answers are grounded in this paper and cite their sources.
Supports cardioprotection with ramipril or bisoprolol during anthracycline chemotherapy; confirms benefit in nonmetastatic breast cancer.
BACKGROUND: Anthracycline-based chemotherapy is a cornerstone in breast cancer treatment but is associated with cardiotoxicity, including subclinical cardiac damage. This study evaluates the efficacy of ramipril and bisoprolol in preventing subclinical cardiac impairment in patients with nonmetastatic breast cancer undergoing anthracycline-based chemotherapy. PATIENTS AND METHODS: The SAFE trial is a multicenter, 2 × 2 factorial, randomized, placebo-controlled, double-blind study involving 262 patients. Participants were allocated to one of four groups: placebo-placebo, ramipril-placebo, bisoprolol-placebo, or ramipril-bisoprolol, administered concurrently with chemotherapy. Subclinical cardiac damage was assessed at 24 months using echocardiographic measures, specifically a ≥10% reduction in three-dimensional left ventricular ejection fraction (3D-LVEF) or global longitudinal strain (GLS). RESULTS: At 24 months, patients receiving ramipril, bisoprolol, or their combination experienced significantly smaller declines in 3D-LVEF compared with placebo (-2.1%, -2.2%, and -3.4%, respectively; all P < 0.001). GLS results were consistent with these findings (P < 0.001). Subclinical cardiac damage occurred in 11.4% of patients receiving ramipril versus 39.3% without ramipril (P < 0.001), and in 9.6% of patients receiving bisoprolol versus 43.5% without bisoprolol (P < 0.001). CONCLUSIONS: Ramipril and bisoprolol significantly reduce the incidence of subclinical cardiac damage in patients with breast cancer undergoing anthracycline-based chemotherapy, thus supporting their use as early prevention cardioprotective strategies.
No takes yet. Share an insight, caveat, or question.
Meattini et al. (2025) conducted an RCT in Nonmetastatic breast cancer undergoing anthracycline-based chemotherapy (n=262). Ramipril and bisoprolol vs. Placebo was evaluated on Subclinical cardiac damage (≥10% reduction in 3D-LVEF or global longitudinal strain) (p=<0.001). Ramipril and bisoprolol reduced subclinical cardiac damage at 24 months compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: